3 Biotech Stocks That Have Already Quadrupled in 2017
It's been a good year for biotech stocks, the iShares Nasdaq Biotechnology index has risen about 26% this year but a handful of companies make the industry tracking index's success seem trivial. Investors that began the year with shares of Kite Pharma Inc. (NASDAQ: KITE), Sangamo Therapeutics Inc. (NASDAQ: SGMO), and Dynavax Technologies Corporation (NASDAQ: DVAX) have already seen the size of their positions quadruple or better in 2017, and they're wondering if there might be further gains ahead.
None of these clinical-stage biotechs have an approved product to sell yet, but that could change soon. Let's look at what's driven these stocks through the roof this year to see if we can expect more gains ahead.
Source: Fool.com
Pfizer Inc. Stock
€28.35
1.870%
With 29 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a positive potential of 44.65% for Pfizer Inc. compared to the current price of 28.35 €.
